News & Events

BD Biosciences, a segment of BD, today announced a licensing and research agreement with Dynomics BV in the fields of leukemia and lymphoma. Under terms of the agreement, BD has an exclusive worldwide license to specific intellectual property related to the flow cytometry detection of fusion proteins. Financial terms were not disclosed.

Fusion proteins are unique proteins generated by a rearrangement of the chromosomes in a cell. Some disease states such as leukemia are characterized and sub-grouped by chromosomal rearrangements that generate well-recognized changes in cellular composition. Detection and identification of these proteins are important markers for diagnosing and monitoring leukemias. Dynomics focuses on the diagnosis and classification of leukemias and malignant lymphomas.

“Dynomics has made significant advances in fusion protein identification and detection technology that fit well with our flow cytometry and bead-based platforms,” said William E. Rhodes, III, President of Cell Analysis, BD Biosciences. “This partnership and important new technology give BD the opportunity to advance technical solutions that can be applied in our core markets of ASR and reagent components used in leukemia and lymphoma testing.”

“BD Biosciences is a recognized world leader in providing reagent components for leukemia and lymphoma testing. We are excited to be partnered with BD to accelerate investigation and development of novel technology that will facilitate progress in the understanding of blood cell malignancies,” said Peter Schoevers, CEO of Dynomics. For more information about Dynomics, visit www.dynomics.nl.

About BD

BD, a leading global medical technology company that makes and sells medical devices, instrumented systems and reagents, is dedicated to improving people’s health throughout the world.BD is focused on improving drug therapy, enhancing the quality and speed of diagnosing infectious diseases, and advancing research and discovery of new drugs and vaccines. The Company’s capabilities are instrumental in combating many of the world’s most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs more than 25,000 people in approximately 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, industry and the general public. For more information, please visit www.bd.com.